综合一区欧美国产,99国产麻豆免费精品,九九精品黄色录像,亚洲激情青青草,久久亚洲熟妇熟,中文字幕av在线播放,国产一区二区卡,九九久久国产精品,久久精品视频免费

您現(xiàn)在的位置: > Language Tips > Audio & Video > Special Speed News  
 





  Once-daily pill could simplify HIV treatment
[ 2006-02-06 15:57 ]


I’m Steve Ember with the VOA Special English Health Report.


Myers Squibb and Gilead Sciences have combined many H.I.V. drugs into a single pill
Sometimes the best medicine is more than one kind of medicine. Malaria, tuberculosis and H.I.V./AIDS, for example, are all treated with combinations of drugs.

But that can mean a lot of pills to take. It would be simpler if drug companies combined all the medicines into a single pill, taken just once a day.

Now, two companies say they have done that for people just starting treatment for H.I.V., the virus that causes AIDS. The companies are Bristol-Myers Squibb and Gilead Sciences.

They have developed a single pill that combines three drugs currently on the market. Bristol-Myers Squibb sells one of them under the name Sustiva. Gilead combined the others, Emtriva and Viread, into a single pill in two thousand four.

Combining drugs involves more than technical issues. It also involves issues of competition if the drugs are made by different companies. The new once-daily pill is the result of what is described as the first joint venture agreement of its kind in the treatment of H.I.V.

In January the New England Journal of Medicine published a study of the new pill. Researchers compared its effectiveness to that of the widely used combination of Sustiva and Combivir. Combivir contains two drugs, AZT and 3TC. The researchers say that after one year of treatment, the new pill suppressed H.I.V. levels in more patients and with fewer side effects.

Gilead paid for the study. Professor Joel Gallant at the Johns Hopkins School of Medicine in Baltimore, Maryland, led the research. He is a paid adviser to Gilead and Bristol-Meyers Squibb as well as the maker of Combivir, GlaxoSmithKline.

GlaxoSmithKline reacted to the findings by saying that a single study is of limited value. It says the effectiveness of Combivir has been shown in each of more than fifty studies.

The price of the new once-daily pill has not been announced. But Gilead and Bristol-Myers Squibb say they will provide it at reduced cost to developing countries.

They plan in the next few months to ask the United States Food and Drug Administration to approve the new pill.

There are limits to who could take it because of the different drugs it contains. For example, pregnant women are told not to take Sustiva because of the risk of birth disorders.

Experts say more than forty million people around the world are living with H.I.V.

This VOA Special English Health Report was written by Cynthia Kirk. Read and listen to our reports at voaspecialenglish.com. I’m Steve Ember.

Vocabulary

 

 

 
 
 




莲花县| 富宁县| 秦皇岛市| 新兴县| 庆阳市| 宜川县| 资源县| 永吉县| 南部县| 芒康县| 正阳县| 鄱阳县| 平安县| 霍林郭勒市| 贵德县| 陈巴尔虎旗| 达州市| 肥乡县| 读书| 桓仁| 二手房| 津南区| 普陀区| 明溪县| 尚义县| 香港 | 从江县| 定远县| 黄浦区| 保德县| 昌平区| 大渡口区| 云和县| 江北区| 余姚市| 南乐县| 彭州市| 甘孜县| 潮州市| 佛山市| 郯城县|